In This Article:
-
Revenue: INR789 crores, highest ever for a quarter.
-
Cost of Goods Sold: Approximately 24% of revenue.
-
Employee Expenses: INR320 crores, impacted by adverse FX movement.
-
Other Expenses: INR130 crores, includes FX loss.
-
EBITDA: INR148 crores, significant growth.
-
Profit Before Tax: INR42 crores.
-
Tax Expense: INR9 crores, about 20-22% of profit before tax.
-
Net Profit: INR33 crores, margin of 4.2%.
-
CRAMS Revenue Growth: 52% increase to INR663 crores.
-
Dutch Facility Revenue: INR55 crores, decline from INR86 crores last year.
-
India CRAMS Revenue Growth: 37% increase to INR49 crores.
-
India (inaudible) Business Revenue: INR21 crores, down from INR27 crores last year.
-
CapEx: INR125 crores for the first half, expected INR250 crores for the full year.
-
Net Debt: Increase due to timing, expected to decrease by year-end.
Release Date: November 14, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Dishman Carbogen Amcis Ltd (BOM:540701) reported its highest-ever quarterly revenue of INR789 crores, driven by increased commercial revenues from Carbogen Amcis and India.
-
The company's new facility in France has been fully validated and is operational, securing a significant contract with a German customer, contributing to a total order value above EUR 10 million.
-
The India CRAMS business showed a growth of 37% compared to the previous year, indicating strong demand and increased order book from existing and new customers.
-
The company is finalizing digitalization efforts, aiming for an operational go-live of the SAP software in the next fiscal year, which is expected to enhance efficiency and profitability.
-
Dishman Carbogen Amcis Ltd (BOM:540701) is on track to achieve its revenue target of CHF255 million for the year, with expectations of increased profitability in the next fiscal year.
Negative Points
-
The company is experiencing a slowdown in capturing new business due to delayed investments in biotech funding, particularly in the U.S., impacting the development project pipeline.
-
The cholesterol and Vitamin D analog business in the Dutch facility saw a decline in revenue due to lower sales, and the market remains challenging post-COVID.
-
The French facility reported an EBITDA loss in the first half of the year, although it is expected to reduce in the second half, indicating ongoing financial challenges.
-
Employee expenses have been impacted by adverse foreign exchange movements, particularly due to costs denominated in Swiss francs.
-
The company's net debt has increased due to higher working capital requirements, and while a reduction is expected by year-end, it remains a concern.